Abstract: The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.
Abstract: The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.
Abstract: A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety.
Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.
Abstract: The invention features methods and compositions for treating and preventing angiogenic disorders and endothelial cells disorders using HspA12B antagonist and HspA12B agonist compounds, respectively.
Type:
Grant
Filed:
August 18, 2006
Date of Patent:
December 11, 2012
Assignees:
Beth Israel Deaconess Medical Center, Inc., Children's Hospital Boston
Inventors:
Vikas P. Sukhatme, Leonard I. Zon, Jenna Galloway
Abstract: The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells. The invention also provides mixed cell populations enriched for a target cell phenotype where the mixed cell population comprises the differentiated in vitro progeny of primate embryonic stem cells.
Type:
Grant
Filed:
June 25, 2010
Date of Patent:
December 4, 2012
Assignee:
Geron Corporation
Inventors:
Jane S. Lebkowski, Catherine A. Priest, Ross M. Okamura
Abstract: As discovered herein, using miRNAs having high homology with both HIV-1 and a co-infecting virus such as HHV-6, HHV-7, or GVB-C, one can inhibit viral replication, more particularly HIV-1 replication using such mutually homologous miRNAs that give rise to the creation of stable triplex formations effective in the downregulation and/or inhibition of viral replication.
Abstract: Laboratory-selected colonies of western corn rootworm exhibiting tolerance to maize containing event DAS-59122-7 are described. Further, methods for various uses of these resistance western corn rootworm colonies are also described, including development of negative cross-resistance strategies and improved resistance management strategies.
Type:
Grant
Filed:
October 3, 2008
Date of Patent:
December 4, 2012
Assignee:
Pioneer Hi-Bred International, Inc.
Inventors:
Rachel Binning, Stephen Lefko, Timothy Nowatzki, Stephen Thompson
Abstract: This invention relates to methods and compositions for enhancing hematopoietic stem cell mobilization by inhibiting early growth response-1 (egr1) activity.
Abstract: The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds with high affinity to at least a portion of a segment of human prostate-derived Ets transcription factor (PDEF). The anti-PDEF antibody of the present invention is effective in prognostic and diagnostic assays for detecting PDEF with immunohistochemistry. The present invention also relates to methods of making the anti-PDEF antibody disclosed herein. The present invention further relates to vaccines against cancers associated with positive expression of PDEF, as well as methods for treating those cancers. Vectors, diagnostic kits, and hybridomas are also disclosed.
Abstract: A liposome preparation is provided. This liposome preparation is capable of stably encapsulating a drug which is unstable under an acidic condition, and such stable encapsulation is realized without detracting the effect realized by the modification of the membrane by a hydrophilic macromolecule such as stability in blood. More specifically, the liposome preparation comprises a unilamellar vesicle formed from a lipid bilayer comprising a phospholipid as its main membrane component, and an interior aqueous phase of the vesicle at a pH of up to 5. The liposome has a drug loaded therein, and the vesicle is modified with a hydrophilic macromolecule only on its exterior surface.
Abstract: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-?.
Abstract: The present invention relates to improved therapies for the treatment of heart disease, particularly the improved delivery of therapeutic agents to heart tissue by direct infusion into the coronary circulation. A preferred embodiment of the invention is a method of treating or preventing a cardiovascular disease by transfecting cardiac cells of a large mammal, the method comprising, identifying a mammal in need of treatment or prevention of heart disease, supplying NO to the coronary circulation prior to, and/or during the infusion of a therapeutic polynucleotide into a blood vessel of the coronary circulation in vivo, where the therapeutic polynucleotide is infused into the blood vessel over a period of at least about three minutes, where the coronary circulation is not isolated or substantially isolated from the systemic circulation of the mammal; and where the therapeutic polynucleotide transfects cardiac cells of the animal resulting in the treatment or prevention of the heart disease.
Abstract: The present invention relates to siRNAs that are targeted to RNAs encoding two or more enzymes of a subfamily of cytochrome P450 (CYP) enzymes, along with vectors, cells, and kits comprising the siRNAs. The invention further relates to methods of decreasing expression of two or more CYP subfamily genes in a non-human animal, animals in which expression of two or more CYP subfamily genes has been decreased, and methods of using such animals to study the function of cytochrome P450 enzymes.
Abstract: Drug delivery compositions and methods of delivering compounds into a cell or into an individual are disclosed. Vaccines and methods of immunizing individuals are disclosed. Compositions for drug delivery including gene therapy and methods of treating individuals using such compositions are disclosed.
Type:
Grant
Filed:
May 28, 2002
Date of Patent:
July 10, 2012
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
David B. Weiner, Karuppiah Muthumani, Donghui Zhang, Mathura P. Ramanathan
Abstract: Biodegradable copolymer hydrogels are provided. The biodegradable copolymer hydrogels have a structure of Formula (I) or Formula (II) A-B—BOX—B-A??Formula (I) B-A-B—(BOX—B-A-B)n-BOX—B-A-B??Formula (II), wherein, A comprises a hydrophilic polyethylene glycol polymer (A); B comprises a hydrophobic polyester polymer (B); BOX is bifunctional group monomer of 2,2?-Bis(2-oxazoline) and used for coupling the blocks A-B or B-A-B; and n is an integer, equal to or greater than 0.
Type:
Grant
Filed:
September 30, 2009
Date of Patent:
July 3, 2012
Assignee:
Industrial Technology Research Institute
Abstract: DCAMKL-1 has been identified as a biomarker for stem cells, as well as cancer stem cells. Methods of detecting the presence of at least one stem cell, methods of isolating stem cells, and methods of inhibiting growth of cancer cells utilizing DCAMKL-1 are disclosed herein.
Type:
Grant
Filed:
May 15, 2009
Date of Patent:
June 12, 2012
Assignee:
The Board of Regents of the University of Oklahoma
Inventors:
Courtney Houchen, Randal May, Shrikant Anant, Sripathi M. Sureban
Abstract: The present invention generally concerns cell therapy and products for use in such therapy. Particularly, the invention provides a preserved cell preparation essentially free of one or more members of a group of cryoprotecting agents consisting of polyalcohols, DMSO and cryoprotecting proteins, the preserved cell preparation comprising somatic cells and at least one polyphenol, wherein upon reconstitution of cells in the cell preparation, at least a portion of said stem cells are viable, said portion being sufficient for use of the cell preparation in stem cell therapy. The invention also provides cells reconstituted from preserved somatic cells, and the use of the reconstituted cells in cell therapy. A preferred cell preparation in accordance with the invention comprises stem cells, preferably human stem cells.
Abstract: The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.
Type:
Grant
Filed:
June 9, 2009
Date of Patent:
June 5, 2012
Assignee:
New York Medical College
Inventors:
Toru Hosoda, Piero Anversa, Annarosa Leri, Jan Kajstura